Effect of pioglitazone on urinary liver‐type fatty acid‐binding protein concentrations in diabetes patients with microalbuminuria

Nakamura, Tsukasa; Sugaya, Takeshi; Kawagoe, Yasuhiro; Ueda, Yoshihiko; Koide, Hikaru

doi:10.1002/dmrr.633

Cited by 39 publications

(24 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, a multicenter trial has shown that urinary L-FABP is more sensitive than urinary protein in predicting the progression of chronic kidney disease [20, 21]. With respect to type 2 diabetic nephropathy [22,23,24] and acute kidney injury [25], urinary L-FABP was reported to reflect the progression of diabetic nephropathy and to be useful for early detection of acute kidney injury. Urinary L-FABP has potential as a clinical marker that could be used to screen for kidney dysfunction and to identify patients who are likely to experience deterioration in renal function.…”

Section: Introductionmentioning

confidence: 99%

Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy

et al. 2009

Self Cite

View full text Add to dashboard Cite

Background: The aims of this clinical study were to investigate the associations of urinary free fatty acid (FFA) levels with tubulointerstitial damage, and to determine the clinical significance of urinary liver-type fatty acid binding protein (L-FABP) in diabetic nephropathy. Methods: Fifteen patients with nephrotic syndrome due to diabetic nephropathy and 12 patients with minimal-change nephrotic syndrome (MCNS) were studied. Urinary and serum FFA concentrations (palmitic, oleic, linoleic, and arachidonic acids) were measured by gas chromatography, and urinary L-FABP levels were quantified using an ELISA technique. Tubulointerstitial damage was assessed using renal biopsy specimens. Results: The levels of urinary linoleic and arachidonic acids were significantly elevated in diabetic nephropathy compared to MCNS patients, though serum FFA levels were lower in diabetic nephropathy than MCNS patients. The degree of tubulointerstitial damage was significantly severer in the patients with diabetic nephropathy than MCNS. Urinary L-FABP and 8-OHdG (8-hydroxydeoxyguanosine) concentrations were significantly higher in the diabetic nephropathy subjects. Conclusion: Elevated urinary excretion of FFA may be a reflection of FFA overload in the proximal tubules, and FFA may be an important promoter of tubulointerstitial damage in diabetic nephropathy patients. Urinary L-FABP levels may reflect the stress induced by FFA to the proximal tubules, leading to severe tubulointerstitial damage.

show abstract

Section: Introductionmentioning

confidence: 99%

Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy

et al. 2009

Self Cite

View full text Add to dashboard Cite

show abstract

“…Median and high dose combinations produced similar effect compared to pioglitazone monotherapy. Pioglitazone, but not nateglinide, is reported to be effective in reducing urinary albumin excretion and the urinary liver-type fatty acid-binding protein level, suggesting role in ameliorating both glomerular and tubulointerstitial lesions associated with early diabetic nephropathy 40 . Pioglitazone play an important role in delaying the progression of tubulointerstitial injury in the patients with diabetic nephropathy.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Nateglinide and Pioglitazone Combination Therapy Compared With Monotherapy on Diabetic Nephropathy

Bigoniya¹,

Malvi²

2017

Int. J. Res. Ayurveda Pharm.

View full text Add to dashboard Cite

The objective of present work is to explore combined effect of nateglinide and pioglitazone on diabetic nephropathy. Nateglinide and pioglitazone were administered to the diabetic nephropathic animals as monotherapy and in median and high dose combination for 28 days. Body weight, relative kidney weight, serum and urine biochemical parameters were analyzed along with kidney tissue antioxidant level and histology. Loss in body weight was efficiently controlled by pioglitazone monotherapy and, nateglinide and pioglitazone high dose combination. Nateglinide treatment significantly (P < 0.05-0.001) reduced serum glucose, blood urea nitrogen (BUN), creatinine and insulin along with decrease in urine albumin and increase in creatinine. Both nateglinide and pioglitazone has significantly (P < 0.05-0.01) reduced glomerular filtration rate (GFR). Nateglinide has nonsignificant effect on kidney antioxidant level but pioglitazone has increased (P < 0.05) superoxide dismutase (SOD) level. Both median and high dose combination significantly (P < 0.05-0.001) reduced the elevated level of serum glucose, cholesterol, triglyceride, low density lipoprotein, BUN, creatinine, insulin and glycated haemoglobin. Combination doses were equally effective in decreasing albumin and increasing creatinine urinary excretion with increase in GFR. High dose combination significantly increased catalase, SOD and glutathione level in the kidney tissue. Monotherapy with nateglinide and pioglitazone reduce hyperglycemia and improve kidney functional ability. Both high and median dose combination of nateglinide and pioglitazone was found effective against disturbed serum and urine biochemical parameters. High dose combination was more effective and beneficial in ameliorating kidney pathological damage and oxidative stress in the treatment of diabetic nephropathy.

show abstract

“…L-FABP is a clinical biomarker of tubulointerstitial damage, which plays an essential role in the progression of chronic kidney disease [13,14] . We reported previously that urinary L-FABP appears to be associated with the progression of diabetic nephropathy [6,7] . Recently, we reported that telmisartan decreased urinary L-FABP levels in a dosedependent manner independent of its blood pressure lowering effect in patients with diabetic nephropathy with renal insufficiency [21] .…”

Section: Discussionmentioning

confidence: 99%

“…A structural resemblance between telmisartan and the PPAR-␥ ligand pioglitazone has been noted [42] . We reported previously that pioglitazone, another PPAR-␥ agonist, is effective in reducing UAE, urinary podocytes, and urinary L-FABP levels [7,43] . The PPAR-␥ agonist may have a specific role in ameliorating progressive tubulointerstitial injury under the hyperglycemic state.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy

Nakamura

Fujiwara

Satô

et al. 2010

Kidney Blood Press Res

Self Cite

View full text Add to dashboard Cite

Background: There is increasing evidence that inhibition of the renin-angiotensin system provides renoprotection independent of blood pressure lowering. The aim of the present study was to determine whether various angiotensin II receptor blockers (ARBs) affect urinary albumin excretion (UAE), urinary liver-type fatty acid-binding protein (L-FABP) and 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels in early-stage diabetic nephropathy patients with microalbuminuria. Methods: Sixty-eight diabetic nephropathy patients with microalbuminuria were randomly allocated to 1 of 4 treatment groups: losartan 100 mg/day (group A), candesartan 12 mg/day (group B), olmesartan 40 mg/day (group C), or telmisartan 80 mg/day (group D). Treatment was continued for 12 months. UAE, L-FABP and 8-OHdG excretion, serum creatinine, and 24-hour creatinine clearance (Ccr) were measured. Results: The serum creatinine and 24-hour Ccr were not affected during the experimental period in any of the groups. Systolic and diastolic blood pressures, UAE, urinary L-FABP and 8-OHdG excretion were significantly reduced after 6 and 12 months compared with baseline in any of the groups. ΔL-FABP and Δ8-OHdG were significantly greater in group D than in the other 3 groups after 12 months. Conclusions: ARBs have renoprotection and this effect of telmisartan appears to be more potent than that of losartan, candesartan, or olmesartan in early-stage diabetic nephropathy patients.

show abstract

Effect of pioglitazone on urinary liver‐type fatty acid‐binding protein concentrations in diabetes patients with microalbuminuria

Abstract: Pioglitazone, but not glibenclamide, voglibose, or nateglinide, appears to be effective in reducing UAE and the urinary L-FABP level, suggesting that pioglitazone has a specific role in ameliorating both glomerular and tubulointerstitial lesions associated with early diabetic nephropathy.

Cited by 39 publications

References 23 publications

Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy

Urinary Fatty Acids and Liver-Type Fatty Acid Binding Protein in Diabetic Nephropathy

Efficacy of Nateglinide and Pioglitazone Combination Therapy Compared With Monotherapy on Diabetic Nephropathy

Renoprotective Effects of Various Angiotensin II Receptor Blockers in Patients with Early-Stage Diabetic Nephropathy

Contact Info

Product

Resources

About